

## Clinical Characteristics And Outcomes Of Patients Newly Diagnosed With Hodgkin Lymphoma: A Multicenter Descriptive Cohort Study

Mai Alalawi<sup>1</sup>, Abdullah M. Alrajhi<sup>2,3</sup>, <u>Amal H. Alotaibi<sup>4</sup></u>, Arwa Alhaj Issa<sup>4</sup>, Areej Abumustafa<sup>4</sup>, Zahra Alhaj Issa<sup>5</sup>, Walaa A Alshahrani<sup>6,7</sup>, Bashayer Alshehri<sup>8</sup>, Ghadah Alyousif<sup>8</sup>, Nora Alkhudair<sup>9</sup>, Nada Alsuhebany<sup>6,8,9</sup>, Mohammed Alzahrani<sup>6,8,9</sup>, Abrar Alghamdi<sup>6,7</sup>, Abeer A. Alenazi<sup>10</sup>, Ramesh Vishwakarma<sup>11</sup>, Khalid Al Sulaiman<sup>6,7,8,12</sup>

<sup>1</sup> Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
<sup>2</sup> Clinical Pharmacy Department, King Fahad Medical City, Riyadh, Saudi Arabia.
<sup>3</sup> Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia
<sup>4</sup> College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.
$^{5}$ Adult Hematology & BMT Department, King Fahad Medical City, Riyadh, Saudi Arabia.
<sup>6</sup> College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.

<sup>7</sup> Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia
<sup>8</sup> Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
<sup>9</sup> Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
<sup>10</sup> Pharmaceutical Care Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
<sup>11</sup> Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
<sup>12</sup> King Abdullah International Medical Research Center-King Saud Bin Abdulaziz University for Health Sc

# Introduction

- Hodgkin Lymphoma (HL) is a prominent B-cell neoplasm, impacting global and Saudi populations.
- The aim of our study is to evaluate the clinical characteristics and outcomes of patients newly diagnosed with HL in Saudi Arabia.

# Objectives

### Con't Table. 1 Baseline characteristic of newly diagnosed cHL patients

Baseline Characteristics	Overall (N=537)
Bulky mediastinal disease or > 10 cm adenopathy, n (%)	155 ( 30.6 )
Nodular sites > 3, n (%)	245 (48.7)
Erythrocyte sedimentation rate >50 mm/hr, n (%)	282 (56.1)
Phenotypes, n (%)	
CD30	486 ( 90.5 )
CD15	391 ( 72.8)
PAX-5	323 ( 60.1)
MUM-1	166 ( 30.9 )

\*Other phenotypes including:CD1, CD5, CD4, CD8, CD38, CD68, CD7, CD21, P53, BCL9, BCL12, FACIN, ALK1, EBER

#### Figure. 2 Initial Stage At The Time Of Diagnosis

### • Primary Outcomes:

Identifying the patient's clinical features: histopathology, risk category, disease stage, and favorable and unfavorable risk factors.

### • Secondary Outcomes:

Complete response (CR) post the initial chemotherapy, Complications post-chemotherapy, Time from HL initial diagnosis to either refractory or relapse (R/R), Progression-free survival (PFS), and Overall survival rate (OS).

## Methods

### Study Design:

A retrospective, descriptive multicenter cohort study, with IRB number NRC23R-637-10.

Inclusion Criteria:




Table. 2 Initial chemotherapy regimens and response assessment in newly diagnosed cHL patients

Regimens and assessment	Overall (N=537)	
Initial chemotherapy used, n (%)		
ABVD	456 (84.9)	
AAVD	32 ( 5.96 )	
Radiotherapy, n (%)	75 (14.0)	

ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine, AAVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine

#### Table. 3 Clinical outcomes of newly diagnosed cHL patients

Outcomes	Overall (N=537)
Overall response rate (CR/PR), n (%)	417 (90.1)
Complete response post chemotherapy (CR), n (%)	387 (83.6)

Patients aged 16 years or older,

Newly diagnosed at three tertiary care hospitals in Saudi Arabia with HL, between January 2016 to December 2021.

### • Exclusion Criteria:

Patients Diagnosed with nodular lymphocyte-predominant HL, Received unknown chemotherapy regimens, Following in another primary center or had incomplete data.

Statistical analysis:

Shapiro–Wilk test and graphical representation (histograms and Q-Q plots) were used to compare numerical variables. Kaplan-Meier plot was used to estimate progression-free survival.


## Results

Figure 1: Eligibility criteria flow diagram.

Patients newly diagnosed with HL at tertiary centers between Jan 2016 and Dec 2021

Overall survival rate, n (%)	501 (94.9)
Disease relapse/refractory, n (%)	95 (17.7)

### Figure. 3 PFS for the entire cohort



#### Table 4: Complications post initial chemotherapy

Complications	Overall (N=537)
Bleomycin induced pulmonary toxicity, n (%)	51 (9.5)
Liver injury, n (%)	23 (4.3)
Hospital admission within 6 months of initial chemotherapy, n (%)	126 (23.5)

## Conclusion




 Table. 1 Baseline characteristic of newly diagnosed cHL patients

Baseline Characteristics	Overall (N=537)
Age at diagnosis (Years), mean (SD)	34.27 (15.7)
Gender – Male, n (%)	289 (53.9)
Comorbidities, n (%)	
Diabetes mellitus	61 ( 11.4)
Hypertension	42 ( 7.8 )
Type of histopathology for cHL, n (%)	
Nodular sclerosis	419 (81.7)
Mixed cellularity	79 (15.4)

- This study provides insights into the clinical features and outcomes of Saudi HL patients. The predominance of the nodular sclerosis subtype and high response rates to ABVD chemotherapy align with global trends, emphasizing the effectiveness of standard treatments for HL in Saudi Arabia.
- Follow-up of long-term survival remains critical due to the unique demographics of the Saudi population and adaptation of new advances in HL treatments.

